Polygenic Scores Derived from Neuroimaging Endophenotypes Predict Outcomes to Psychotherapy and Medication Treatments for Major Depressive Disorder

Biomarkers to guide optimal treatment selection are lacking for major depressive disorder (MDD). Despite some promising findings, candidate gene and genome-wide association studies (GWAS) of antidepressant response have met with little success and none has focused on differential outcome to mechanistically different treatments. Development of such biomarkers would allow to better match patients with their most favourable treatment and has direct implications for the development of precision biology-based clinical practice.